Healthcare
Actis considers Sterling exit
Actis, a London-headquartered emerging markets investor, is set to exit its 80% stake in Gujarat-based Sterling Add-Life Medical Institute, the Business Standard reported, citing sources close to the deal.
Warburg Pincus to sell Max Healthcare stake to Max India
Max India, an insurer and hospital operator, plans to buy a 16.37% stake in its subsidiary Max Healthcare from Warburg Pincus, Economic Times reported.
Goldman Sachs takes minority stake in Max India
Goldman Sachs’s private equity unit will acquire a 9.4% stake in Max India, an insurer and hospital operator, for $115 million, according to reports.
Private equity-backed Apo Plus Station makes healthcare acquisition
Apo Plus Station, a portfolio company of Japanese private equity firm J-Star, has purchased a 40% stake in EBM, a clinical examinations specialist.
CDC to target Asia, Africa investments exclusively
CDC, a development finance institution that makes private equity investments in emerging markets on the behalf of the UK government, will focus exclusively on South Asia and sub-Saharan Africa, following a year-long review of its activities. These areas...
PE targets Australian healthcare
AT A TIME WHEN PROFITABLE EXITS in Australia are difficult to achieve due to the lingering effects of the global financial crisis, private equity firms continue to rely on healthcare for returns. This strategy received a ringing endorsement last week...
Indian affordable healthcare group secures $10m in venture funding
Singapore’s Aquarius India Fund and Seedfund have participated in a $10 million third round of funding for Vaatsalya Healthcare, which operates in semi-urban and rural India, Economic Times reported. Bangalore-based Vaatsalya will use the capital to expand...
PE-backed Royal Adelaide Hospital set for construction
The private equity backers of the SA Health Partnership have finalized the A$1.85 billion ($1.9 billion) construction of the new Royal Adelaide Hospital, touted as one of the market’s largest public-private partnerships (PPP) to date.
TPG, Warburg Pincus consider $100m investment in Vasan
TPG and Warburg Pincus are in talks with India’s Vasan Healthcare over a potential $100 million investment that would be structured as a combination of primary and secondary transactions, the Business Standard reported. A spokesperson for Vasan Group...
Vivo Ventures names China head
Life science VC firm Vivo Ventures has promoted two professionals to the role of Managing Partners, including James Zhao, who will now head the firm’s China team in light of the promotion.
Intel Capital invests $18m more in India, including first healthcare investment
Intel Capital, the PE investment arm of Intel, has invested $18 million in two Indian companies, including Sudhir Srivastava Robotic Surgery Centre (SSARSC), a provider of advanced robotic surgery procedures, marking Intel Capital’s first investment in...
Japan's Takeda provides exit for European PE firm
Takeda Pharmaceutical Co, one of the largest pharmaceutical companies in Japan has reportedly planned to take over Zurich-headquartered pharmaceutical maker Nycomed, which is owned by European private equity firm Nordic Capital and Credit Suisse’s private-equity...
J-Star makes second healthcare acquisition
Japanese private equity firm J-Star has made another investment in Japan’s growing healthcare sector, taking a majority stake in HCM, KK, a domestic provider of in-home care services, via a management buyout. Financial details were not disclosed, but...
China-focused VCs invest in oncology research firm
Oncology and R&D-focused Crown Bioscience has completed a $28.8 million Series C round of financing, led by OrbiMed Advisors Caduceus Asia Partners Fund. China-based Qiming Venture Partners and CRCI, both existing investors, also participated, as well...
Japan's J-Star makes another healthcare buy
Tokyo-based J-Star has taken a majority stake in HCM, KK., a domestic provider of in-home care services, for undisclosed sum.
Chinese cactus-product maker gets $1.5m
Kodiak Capital Group, LLC, a New York-based PE investor, has strengthened its ties to the unique-concept firm China Kangtai Cactus Biotech Inc., a developer and producer of cactus-derived health and nutrition products, injecting $1.5 million into the...
CVC's I-Med faces debt restructure
CVC Asia Pacific is reportedly set to present a restructuring plan to senior lenders of Sydney-based diagnostic imaging firm I-Med in an effort to find respite from its A$890 million worth of debt owed.
SciClone buys VC-backed NovaMed
California-based SciClone Pharmaceuticals Inc. has acquired Fidelity Asia Ventures- and Atlas Venture-backed NovaMed Pharmaceuticals Inc., a Chinese specialty pharmaceutical firm, for approximately $62 million in the form of cash and shares.
PRC drug company Ascletis raises $100 million
Newly launched Chinese pharmaceutical company Ascletis Inc. – which aims to license high-potential drug products from Western companies and develop them into medicines for China’s fast- growing market – has raised $100 million in private funding tranche...
Kunming drug distributer gets funding
Kunming-based medical logistics and distribution company First China Pharmaceutical Group has received $2.7 million from a group led by New York-based investment and merchant bank Wellfleet Partners. Three institutional investors, including existing backer,...
RaQualia Pharma postpones Japan IPO
Private equity-backed RaQualia Pharma Inc., an Aichi-based specialized marketing and intellectual property firm servicing the pharmaceutical industry, has announced the postponement of its IPO onto the Osaka Stock Exchange JASDAQ Growth Market due to...
Mount Kellett considers Indian pharma investment
US private equity group Mount Kellett Capital Management is reportedly making an INR410 crore ($90 million) investment in MedPlus Health Services, one of India's top pharmaceutical retailers, based in Hyderabad. Mount Kellett aims to make its capital...
Temasek sells out of Thai hospital; on the sly?
This week, a letter to the Stock Exchange of Thailand revealed that a 12.6% stake in Bumrungrad Hospital had been sold mid-January by several investors, one of which included Singaporean sovereign wealth fund, Temasek Holdings. Interestingly, the letter...
Valiant exits Japanese drug dispensary group
Valiant Partners Co., a SME-focused private equity firm, has exited its stake in portfolio company Hanshin Dispensing Pharmacy Co., a Kobe-based pharmacy chain operator. The fund sold its entire stake to a holding company owned by the Iwasaki family,...